Use of compounds being combined selective dopamine D2 receptor antagonists and 5-HT
1A
receptor agonists, in particular (R)-(−)-2-[5-4 fluorophenyl)-3-pyridylmethyl-aminomethyl]-chromane or a physiologically acceptable salt thereof or N-(4′-fluoro-3-biphenylmethyl)-N-2-(3-cycanophenoxy-ethyl)-amine or a physiologically acceptable salt thereof, for the manufacture of a medicament for use in veterinary medicine for the treatment of self directed traumatic disorders associated with behavioral stressors, compulsive disorders associated with behavioral stressors and/or anxiety disorders associated with behavioral stressors.
结合使用选择性
多巴胺 D2 受体拮抗剂和 5-HT
1A
受体激动剂,特别是(R)-(-)-2-[5-4-
氟苯基)-3-
吡啶甲基-
氨甲基]-
色烷或其生理学上可接受的盐或 N-(4′-
氟-3-
联苯基甲基)-N-2-(3-
氰基苯氧基乙基)-胺或其生理学上可接受的盐,用于制造兽医用药,以治疗与行为应激源相关的自导创伤障碍、与行为应激源相关的强迫障碍和/或与行为应激源相关的焦虑障碍。